Lv1
58 积分 2026-04-01 加入
OA08.04 Primary Endpoint Results from SHERLOCK: a Phase 2 trial of Sotorasib, Bevacizumab and Chemotherapy in Advanced KRAS G12C NSCLC
23天前
已关闭
D3S-001 in advanced solid tumors with KRASG12C mutations: a phase 1 trial
26天前
已完结
Garsorasib在中国KRAS突变非小细胞肺癌患者中的应用：一项开放标签、多中心、单臂、二期临床试验
1个月前
已完结
Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments
1个月前
已完结
Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial
1个月前
已完结
Glecirasib plus sitneprotafib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial
1个月前
已完结
皖公网安备34019202002308
